Product Name Catalog # Price (NP)**   Qty
EGFR T790M Stably Expressing 293 Cell Line EL-018-NP $1,200
- +
  • ** Non Profit (NP) price is for academic, non profit organizations and institutes
Description:

Epidermal growth factor receptor (EGFR) is a cell-surface receptor with intrinsic intracellular protein-tyrosine kinase (TK) activity. Ligand binding induces EGFR dimerization and phosphorylation, leading to the activation of EGFR signaling pathway. In several malignancies such as non-small cell lung cancer (NSCLC), EGFR signaling is deregulated due to mutations in EGFR, which results in uncontrolled proliferation and migration of tumor cells. EGFR mutations can lead to “oncogene-addicted” cancers, where the tumor cells depend on the mutated EGFR for cell survival and malignant phenotype.  One of the most common EGFR mutations found in human patients is L858R substitution in exon 21, within the activation loop of EGFR. Patients with this mutation are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib, whereas patients with wild type EGFR are not sensitive to TKI. Another clinically relevant mutation associated with acquired gefitinib and erlotinib resistance is T790M, found in exon  20. Cells expressing EGFR with both L858R and T790M mutations are resistant to induced apoptosis in the presence of gefitinib or erlotinib.

We offer EL-018, a 293 stable cell line expressing EGFR T790M. The EGFR T790M mutation arises from the nucleotide change c.2369C>T in exon 20, resulting in an amino acid substitution of the threonine (T) at position 790 by a methionine (M). This cell line can be used to study the molecular mechanism underlying susceptibility of tumors to the drugs (i.e. gefitinib and erlotinib) as well as screening and validating new TKIs.


Data

Dose-dependent growth inhibition of 293 cells harboring EGFR T790M (EL-018) and control 293 cell line. The cells were treated with the indicated dose of erlotinib for 72 hours and cell viability was measured using Signosis CVC reagent. EGFR T790M mutation stably expressing 293 cells were more resistant to TKI erlotinib than control.